JP6218147B2 - 標識されたｈｓｐ９０阻害剤の使用 - Google Patents

標識されたｈｓｐ９０阻害剤の使用 Download PDF

Info

Publication number
JP6218147B2
JP6218147B2 JP2014520227A JP2014520227A JP6218147B2 JP 6218147 B2 JP6218147 B2 JP 6218147B2 JP 2014520227 A JP2014520227 A JP 2014520227A JP 2014520227 A JP2014520227 A JP 2014520227A JP 6218147 B2 JP6218147 B2 JP 6218147B2
Authority
JP
Japan
Prior art keywords
hsp90
tumor
cells
cancer
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014520227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527620A (ja
Inventor
チオシス、ガブリエラ
タルドネ、トニー
アルポーグ、メリー・エル．
ゴメス—ダガマ、エリカ・エム．
ゴメス―ダガマ、エリカ・エム．
グズマン、モニカ・エル．
ゾン、ホンリャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of JP2014527620A publication Critical patent/JP2014527620A/ja
Application granted granted Critical
Publication of JP6218147B2 publication Critical patent/JP6218147B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2014520227A 2011-07-08 2012-07-06 標識されたｈｓｐ９０阻害剤の使用 Expired - Fee Related JP6218147B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161506010P 2011-07-08 2011-07-08
US61/506,010 2011-07-08
PCT/US2012/045864 WO2013009657A1 (en) 2011-07-08 2012-07-06 Uses of labeled hsp90 inhibitors

Publications (2)

Publication Number Publication Date
JP2014527620A JP2014527620A (ja) 2014-10-16
JP6218147B2 true JP6218147B2 (ja) 2017-10-25

Family

ID=47506428

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014520227A Expired - Fee Related JP6218147B2 (ja) 2011-07-08 2012-07-06 標識されたｈｓｐ９０阻害剤の使用
JP2014520226A Expired - Fee Related JP6054389B2 (ja) 2011-07-08 2012-07-06 標識されたｈｓｐ９０阻害剤の使用
JP2016232580A Expired - Fee Related JP6662759B2 (ja) 2011-07-08 2016-11-30 標識されたｈｓｐ９０阻害剤の使用
JP2019125455A Pending JP2019194232A (ja) 2011-07-08 2019-07-04 標識されたｈｓｐ９０阻害剤の使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014520226A Expired - Fee Related JP6054389B2 (ja) 2011-07-08 2012-07-06 標識されたｈｓｐ９０阻害剤の使用
JP2016232580A Expired - Fee Related JP6662759B2 (ja) 2011-07-08 2016-11-30 標識されたｈｓｐ９０阻害剤の使用
JP2019125455A Pending JP2019194232A (ja) 2011-07-08 2019-07-04 標識されたｈｓｐ９０阻害剤の使用

Country Status (13)

Country Link
US (4) US20140294725A1 (enExample)
EP (3) EP3208615B1 (enExample)
JP (4) JP6218147B2 (enExample)
KR (2) KR102025142B1 (enExample)
CN (3) CN104081206B (enExample)
AU (3) AU2012282905B8 (enExample)
BR (1) BR112014000445A2 (enExample)
CA (2) CA2841173C (enExample)
DK (1) DK2729806T3 (enExample)
EA (1) EA201490230A1 (enExample)
ES (2) ES2624982T3 (enExample)
MX (2) MX347607B (enExample)
WO (2) WO2013009657A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
EP3208615B1 (en) * 2011-07-08 2019-10-09 Sloan Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
MY199894A (en) 2012-12-21 2023-11-27 Epizyme Inc Prmt5 inhibitors and uses thereof
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
CN103279964B (zh) * 2013-04-23 2015-10-28 浙江大学 一种基于prca的pet图像动态重建方法及系统
WO2015023976A2 (en) 2013-08-16 2015-02-19 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof
WO2015038649A1 (en) * 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
JP6497767B2 (ja) * 2013-12-16 2019-04-10 日本化薬株式会社 癌治療におけるｈｓｐ９０阻害剤の抗腫瘍効果を予測する方法
JP6491214B2 (ja) * 2013-12-23 2019-03-27 メモリアル スローン ケタリング キャンサー センター 放射性標識のための方法および試薬
EP2942629A1 (en) * 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
JP6835709B2 (ja) * 2014-09-17 2021-02-24 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ９０を標的とした炎症及び感染のイメージング及び療法
TW201722422A (zh) 2015-10-05 2017-07-01 美國紀念斯隆-凱特琳癌症中心 用於治療癌症之合理組合療法
KR102007135B1 (ko) 2017-03-20 2019-08-02 포르마 세라퓨틱스 인크. 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물
CN111386351A (zh) 2017-09-22 2020-07-07 华盛顿大学 细胞分子的原位组合标记
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
WO2020078924A1 (en) 2018-10-15 2020-04-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compounds for treatment of diseases and methods of screening therefor
AU2020219368A1 (en) 2019-02-08 2021-07-15 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
JP2022532661A (ja) * 2019-05-15 2022-07-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 薬剤－凝縮物相互作用を特徴付け及び利用する方法
KR20220084047A (ko) 2019-09-18 2022-06-21 듀포인트 테라퓨틱스, 인크. 응축물 관련 특이성에 대한 스크리닝 방법 및 이의 용도
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
JP7589935B2 (ja) * 2019-10-31 2024-11-26 キヤノンメディカルシステムズ株式会社 解析装置および解析プログラム
EP4204561A4 (en) * 2020-10-02 2025-02-26 The Trustees Of Dartmouth College METHODS AND MEANS FOR THE TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASES AND FOR THE EVALUATION
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113025715A (zh) * 2021-03-23 2021-06-25 中山大学附属第一医院 Hop在预测胃癌预后中的应用
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
CN116813622A (zh) * 2023-05-19 2023-09-29 中国科学院基础医学与肿瘤研究所(筹) 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7156111B2 (en) * 2001-07-16 2007-01-02 Akrion Technologies, Inc Megasonic cleaning using supersaturated cleaning solution
AU2002364566B2 (en) * 2001-12-12 2009-03-26 Conforma Therapeutics Corporation Assays and implements for determining and modulating HSP90 binding activity
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
EP1457499A1 (en) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
US7959915B2 (en) * 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
WO2005012482A2 (en) * 2003-06-30 2005-02-10 Sloan-Kettering Institute For Cancer Research Assay for identification of bioactive compounds that interact with heat shock protein 90
WO2005021552A1 (en) 2003-08-29 2005-03-10 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
GB0323810D0 (en) 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
JP2007526761A (ja) * 2003-10-31 2007-09-20 ヴィタテックス， インコーポレイテッド 循環性の腫瘍細胞および内皮細胞の検出のための血液試験のプロトタイプおよび方法
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
WO2007047955A2 (en) * 2005-10-21 2007-04-26 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
CA2653222A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DK2034839T3 (en) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Res TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90
US8580519B2 (en) * 2006-11-27 2013-11-12 University Of Maryland, Baltimore Use of plasma HSP90 related to malignancy
CN101627121A (zh) * 2006-12-08 2010-01-13 奥斯瑞根公司 作为治疗干预的靶标的miRNA调控基因和路径
JP2010526280A (ja) * 2007-04-13 2010-07-29 ファーマサイクリックス，インク． ヒストンデアセチラーゼインヒビターの薬効バイオマーカーとしてのカルシウム流動
EP2200653A2 (en) * 2007-09-10 2010-06-30 University of Massachusetts Mitochondria-targeted anti-tumour agents
WO2009049184A2 (en) * 2007-10-12 2009-04-16 Transmolecular, Inc. Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
EP2224804A4 (en) * 2007-12-07 2011-06-01 Bipar Sciences Inc TREATMENT OF CANCER WITH COMBINATIONS OF TOPOÎSOMERASE INHIBITORS AND PARP INHIBITORS
EP2385370A1 (en) * 2008-04-10 2011-11-09 Massachusetts Institute of Technology (MIT) Methods for identification and use of agents targeting cancer stem cells
US20110319415A1 (en) 2008-08-18 2011-12-29 Universit+e,uml a+ee t zu K+e,uml o+ee ln Susceptibility to HSP90-Inhibitors
US9567318B2 (en) * 2009-08-17 2017-02-14 Memorial Sloan-Kettering Cancer Center Substituted pyrimidine compounds and uses thereof
KR102129420B1 (ko) 2009-10-07 2020-07-03 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 저해제로서 유용한 퓨린 유도체
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
KR101984480B1 (ko) 2011-04-05 2019-05-31 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
NZ618062A (en) 2011-04-28 2016-04-29 Sloan Kettering Inst Cancer Hsp90 combination therapy
EP3208615B1 (en) 2011-07-08 2019-10-09 Sloan Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2015089402A1 (en) 2013-12-12 2015-06-18 The University Of Chicago Methods and compositions related to hsp90 inhibitors and breast cancer
JP6835709B2 (ja) 2014-09-17 2021-02-24 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ９０を標的とした炎症及び感染のイメージング及び療法

Also Published As

Publication number Publication date
NZ620634A (en) 2016-07-29
CA2841173C (en) 2022-06-21
HK1243175A1 (en) 2018-07-06
AU2012282905A8 (en) 2017-08-31
EP2729806B1 (en) 2017-02-22
JP6662759B2 (ja) 2020-03-11
EP3208615B1 (en) 2019-10-09
WO2013009655A2 (en) 2013-01-17
KR102138218B1 (ko) 2020-07-28
JP2014527620A (ja) 2014-10-16
BR112014000445A2 (pt) 2017-06-27
WO2013009655A3 (en) 2013-05-10
US20240058482A1 (en) 2024-02-22
AU2012282905A1 (en) 2014-02-13
CN104081203B (zh) 2018-07-31
AU2012282903A1 (en) 2014-02-13
ES2624982T3 (es) 2017-07-18
US9555137B2 (en) 2017-01-31
AU2017204369A1 (en) 2017-07-20
JP2019194232A (ja) 2019-11-07
AU2017204369B2 (en) 2019-08-01
CN104081206B (zh) 2017-06-09
CN104081203A (zh) 2014-10-01
JP2017121233A (ja) 2017-07-13
CA2841069A1 (en) 2013-01-17
EP2729806A4 (en) 2015-04-01
AU2012282905B2 (en) 2017-04-06
KR20140075667A (ko) 2014-06-19
MX347607B (es) 2017-05-04
AU2012282905B8 (en) 2017-08-31
US11607465B2 (en) 2023-03-21
KR20170042805A (ko) 2017-04-19
JP2014525908A (ja) 2014-10-02
MX2014000292A (es) 2015-03-06
US20140294725A1 (en) 2014-10-02
KR102025142B1 (ko) 2019-09-26
US20210138091A1 (en) 2021-05-13
EP2729806A1 (en) 2014-05-14
DK2729806T3 (en) 2017-05-15
CN109374889A (zh) 2019-02-22
MX2014000286A (es) 2015-03-06
EP3208615A2 (en) 2017-08-23
CA2841173A1 (en) 2013-06-17
EP3208615A3 (en) 2017-11-01
CN104081206A (zh) 2014-10-01
JP6054389B2 (ja) 2016-12-27
CN109374889B (zh) 2022-04-19
EA201490230A1 (ru) 2014-06-30
US20140242602A1 (en) 2014-08-28
EP3709022A1 (en) 2020-09-16
ES2766623T3 (es) 2020-06-12
CA2841069C (en) 2021-11-23
WO2013009657A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
US20240058482A1 (en) Uses of labeled hsp90 inhibitors
HK40039014A (en) Uses of labeled hsp90 inhibitors
Class et al. Patent application title: USES OF LABELED HSP90 INHIBITORS Inventors: Gabriela Chiosis (New York, NY, US) Gabriela Chiosis (New York, NY, US) Tony Taldone (New York, NY, US) Mary L. Alpaugh (Teaneck, NJ, US) Erica M. Gomes-Dagama (New Rochelle, NY, US) Monica L. Guzman (New York, NY, US) Hongliang Zong (New York, NY, US) Assignees: CORNELL UNIVERSITY SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
HK40005114A (en) Uses of labeled hsp90 inhibitors
HK40005114B (en) Uses of labeled hsp90 inhibitors
HK1243175B (en) Uses of labeled hsp90 inhibitors
HK1192943B (en) Uses of labeled hsp90 inhibitors
HK1192943A (en) Uses of labeled hsp90 inhibitors
NZ620634B2 (en) Uses of labeled hsp90 inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150701

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170822

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170919

R150 Certificate of patent or registration of utility model

Ref document number: 6218147

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees